5-HT3 antagonist for cognition improvement in schizophrenia: a double blind, placebo-controlled trial

5-HT3 antagonist for cognition improvement in schizophrenia: a double blind, placebo-controlled trial

Show other versions (1)

Abstract Introduction: Patients with schizophrenia characteristically exhibit cognitive deficits. The level of cognitive impairment is found to predict the functional outcome of the illness more strongly than the severity of positive or negative symptoms. The purpose of this study was to assess th...

Full description

Bibliographic Details
Main Authors:	Neyousha Mohammadi, Maryam Noroozian, Naregs Karamghadiri, Shahin Akhondzadeh
Format:	Article
Language:	English
Published:	Iran University of Medical Sciences 2010-01-01
Series:	Basic and Clinical Neuroscience
Subjects:	Cognitive impairments 5- HT3 Schizophrenia
Online Access:	http://bcn.tums.ac.ir/browse.php?a_code=A-10-1-19&slc_lang=en&sid=1

Similar Items

5-HT3 antagonist for cognition improvement in schizophrenia: a double blind, placebo-controlled trial
by: Neyousha Mohammadi, et al.
Published: (2010-01-01)

Ritanserin as an adjunct to lithium and haloperidol for the treatment of medication-naive patients with acute mania: a double blind and placebo controlled trial
by: Mohammadi Mohammad, et al.
Published: (2003-06-01)

The therapeutic effect of quetiapine on cognitive impairment associated with 5-HT1A presynaptic receptor involved schizophrenia
by: Dai Han, Shenxun Shi, Hong Luo
Published: (2019-09-01)

Acetaminophen as Adjuvant to Risperidone in Chronic Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
by: Somaye Arabzadeh, et al.
Published: (2018-02-01)

Efficacy of Spironolactone as an Adjunctive Therapy to Risperidone to Improve Symptoms of Schizophrenia: A Double-Blind, Randomized, Placebo-Controlled, Clinical Trial
by: Atefeh Zandifar, et al.
Published: (2021-12-01)

The Effect of Aspirin on Schizophrenia; A Double Blind Placebo Controlled Study
by: Hamidreza Jamilian, Gevick Hacoupian
Published: (2017-12-01)

Adjunctive simvastatin treatment in schizophrenia patients; a double blind randomized and placebo controlled trial
by: Somaieh Ashrafi, et al.
Published: (2022-01-01)

Effects of High-Frequency rTMS on Negative Symptoms and Cognitive Function in Hospitalized Patients With Chronic Schizophrenia: A Double-Blind, Sham-Controlled Pilot Trial
by: Na Wen, et al.
Published: (2021-09-01)

A Placebo-Controlled Study of Raloxifene Added to Risperidone in Men with Chronic Schizophrenia
by: Mohammad-Reza Khodaie-Ardakani, et al.
Published: (2015-06-01)

Pharmacotherapy of Schizophrenia: Ploypharmacy Approaches
by: Fatemeh Rahiminejad, et al.
Published: (2010-08-01)

Pharmacotherapy of Schizophrenia: Ploypharmacy Approaches
by: Fatemeh Rahiminejad, et al.
Published: (2010-07-01)

Cannabis use and cognitive impairment in schizophrenia
by: M. Gonçalves, et al.
Published: (2022-06-01)

Efficacy and safety of lurasidone in adolescents and young adults with schizophrenia: Pooled analysis of double-blind, placebo-controlled 6-week studies
by: F. Calisti, et al.
Published: (2021-04-01)

Toxoplasma gondii seropositivity and cognitive function in adults with schizophrenia
by: Ivanka Veleva, et al.
Published: (2022-12-01)

The role of the insula in cognitive impairment of schizophrenia
by: Susanna Gebhardt, et al.
Published: (2023-06-01)

5-HT attenuates chronic stress-induced cognitive impairment in mice through intestinal flora disruption
by: Junxing Ma, et al.
Published: (2023-02-01)

High-Dose Betahistine Improves Cognitive Function in Patients With Schizophrenia: A Randomized Double-Blind Placebo-Controlled Trial
by: Yongqian Wang, et al.
Published: (2021-11-01)

Ginkgo biloba for Improvement of Memory and Quality of Life in Multiple Sclerosis: an Open Trial
by: M Noroozian, et al.
Published: (2011-09-01)

Tandospirone, a 5-HT1A partial agonist, ameliorates aberrant lactate production in the prefrontal cortex of rats exposed to blockade of N-methy-D-aspartate receptors; Towards the therapeutics of cognitive impairment of schizophrenia
by: Takashi eUehara, et al.
Published: (2014-09-01)

Amisulpride augmentation therapy improves cognitive performance and psychopathology in clozapine-resistant treatment-refractory schizophrenia: a 12-week randomized, double-blind, placebo-controlled trial
by: Ming-Huan Zhu, et al.
Published: (2022-10-01)

Cognitive impairments in schizophrenia and their impact on oxidative stress
by: A. S. Piatoikina, et al.
Published: (2022-10-01)

Associations of cognitive impairment in patients with schizophrenia with genetic features and with schizophrenia-related structural and functional brain changes
by: Chuanjun Zhuo, et al.
Published: (2022-08-01)

Cognitive impairment in treatment-refractory schizophrenia and type i diabetes. A case
by: L. Soldado Rodriguez, et al.
Published: (2021-04-01)

Serum C-Reactive Protein in Patients with Deficit Schizophrenia and the Relationship with Cognitive Function
by: Pan LH, et al.
Published: (2020-12-01)

Azologization of serotonin 5-HT3 receptor antagonists
by: Karin Rustler, et al.
Published: (2019-03-01)

Novel 5-HT5A receptor antagonists ameliorate scopolamine-induced working memory deficit in mice and reference memory impairment in aged rats
by: Mayako Yamazaki, et al.
Published: (2015-03-01)

Amisulpride augmentation in clozapine-unresponsive schizophrenia (AMICUS): a double-blind, placebo-controlled, randomised trial of clinical effectiveness and cost-effectiveness
by: Thomas RE Barnes, et al.
Published: (2017-09-01)

Association analysis between the C516T polymorphism in the 5-HT2A receptor gene and schizophrenia Análise de associação entre o polimorfismo C516T do gene do receptor 5-HT2A e esquizofrenia
by: Vivian Bertola, et al.
Published: (2007-03-01)

5-HT3 receptor antagonists protect against pressure overload-induced cardiac hypertrophy in murine
by: Rong Huo, et al.
Published: (2012-02-01)

Mismatch negativity as an early biomarker of cognitive impairment in schizophrenia
by: Abeer Mamdouh Ali Mahmoud, et al.
Published: (2023-02-01)

Repetitive transcranial magnetic stimulation as an adjunctive treatment for negative symptoms and cognitive impairment in patients with schizophrenia: a randomized, double-blind, sham-controlled trial
by: Zhuo K, et al.
Published: (2019-05-01)

Tolerability of cariprazine in the early stage of schizophrenia: A pooled, post-hoc analysis of 4 phase ii/iii double-blind placebo-controlled trials
by: Z.B. Dombi, et al.
Published: (2021-04-01)

Cognitive impairment in patients with schizophrenia: A comparative study from western Rajasthan
by: Nikita Dhaka, et al.
Published: (2020-01-01)

Relationships Among Retinal Nerve Fiber Layer Thickness, Vascular Endothelial Growth Factor, and Cognitive Impairment in Patients with Schizophrenia
by: Liu Y, et al.
Published: (2021-12-01)

Current Limitations and Candidate Potential of 5-HT7 Receptor Antagonism in Psychiatric Pharmacotherapy
by: Ruri Okubo, et al.
Published: (2021-02-01)

Cognitive symptoms associated with antipsychotic course experience in residual schizophrenia
by: D. Safonov
Published: (2021-06-01)

Cognitive function in schizophrenia and its association with socio-demographics factors
by: Bharti T Talreja, et al.
Published: (2013-01-01)

NLRP3 Influences Cognitive Function in Schizophrenia in Han Chinese
by: Ruimei Liu, et al.
Published: (2021-12-01)

Subjectively-assessed cognitive impairment and neurocognition associations in schizophrenia inpatients
by: Tatsuhiko Masuzawa, et al.
Published: (2022-03-01)

Word and nonword repetition in patients with Schizophrenia
by: Alireza Farnam, et al.
Published: (2015-08-01)